GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Shiller PE Ratio

IGC Pharma (IGC Pharma) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


IGC Pharma Shiller PE Ratio Historical Data

The historical data trend for IGC Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Shiller PE Ratio Chart

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IGC Pharma's Shiller PE Ratio

For the Biotechnology subindustry, IGC Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Shiller PE Ratio falls into.



IGC Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

IGC Pharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, IGC Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.09/129.4194*129.4194
=-0.090

Current CPI (Dec. 2023) = 129.4194.

IGC Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.170 99.695 -0.221
201406 -0.120 100.560 -0.154
201409 -0.070 100.428 -0.090
201412 -0.050 99.070 -0.065
201503 -0.090 99.621 -0.117
201506 -0.030 100.684 -0.039
201509 -0.040 100.392 -0.052
201512 -0.020 99.792 -0.026
201603 -0.080 100.470 -0.103
201606 -0.020 101.688 -0.025
201609 -0.020 101.861 -0.025
201612 -0.004 101.863 -0.005
201703 -0.030 102.862 -0.038
201706 -0.020 103.349 -0.025
201709 -0.010 104.136 -0.012
201712 -0.020 104.011 -0.025
201803 -0.020 105.290 -0.025
201806 -0.020 106.317 -0.024
201809 -0.030 106.507 -0.036
201812 -0.030 105.998 -0.037
201903 -0.060 107.251 -0.072
201906 -0.030 108.070 -0.036
201909 -0.030 108.329 -0.036
201912 -0.040 108.420 -0.048
202003 -0.080 108.902 -0.095
202006 -0.050 108.767 -0.059
202009 -0.040 109.815 -0.047
202012 -0.060 109.897 -0.071
202103 -0.070 111.754 -0.081
202106 -0.040 114.631 -0.045
202109 -0.090 115.734 -0.101
202112 -0.050 117.630 -0.055
202203 -0.120 121.301 -0.128
202206 -0.050 125.017 -0.052
202209 -0.050 125.227 -0.052
202212 -0.040 125.222 -0.041
202303 -0.080 127.348 -0.081
202306 -0.040 128.729 -0.040
202309 -0.050 129.860 -0.050
202312 -0.090 129.419 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IGC Pharma  (AMEX:IGC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


IGC Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (IGC Pharma) Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma (IGC Pharma) Headlines

From GuruFocus